RS for 40-year-old, 0.8-cm node-neg ER+ IDC? A pt w/ 3.0-cm tumor?
Would you order an Oncotype DX assay for a 40 yo premenopausal woman with a 0.8-cm, node-negative, ER-positive, HER2-negative IDC?
Would you order an Oncotype DX assay for a 40 yo premenopausal woman with a 3.0-cm, node-negative, ER-positive, HER2-negative IDC?
Ellis MJ et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 2012;486(7403):353-60.Abstract
Kelly CM et al. A comparative analysis of distant recurrence risk assessments by Oncotype DX recurrence score alone and integrated with clinicopathologic factors in early-stage breast cancer. Proc ASCO 2013;Abstract 598.
Solin LJ et al. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst 2013;105(10):701-10. Abstract
Tang G et al. Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: Recurrence score alone and integrated with pathologic and clinical factors. J Clin Oncol 2011;29(33):4365-72. Abstract